by The Acellular Dermal Matrices Market is estimated to be valued at US$ 12.1 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Acellular dermal matrices are human or animal-derived tissue allografts used in plastic and reconstructive surgeries to provide strength, support and enable for tissue regeneration in various hernia repairs, breast reconstructions and other reconstructive procedures. They act as scaffolds for new connective tissue to grow into.
Market Dynamics:
The growth of the acellular dermal matrices market is driven by increasing prevalence of injuries, congenital deformities and cancer surgery resulting in defects requiring reconstruction procedures. As per the American Burn Association, over 450,000 burn injuries require medical care each year in the United States. According to the Centers for Disease Control and Prevention, one in three melanomas are attributed to sunburns received as children and adolescents. These statistics indicate significant opportunities for acellular dermal matrices in burn injury and cancer repair procedures. Additionally, rising healthcare expenditures, improved access to surgeries and growing medical tourism are also boosting the market growth.
Market Key Trends:
The acellular dermal matrices market has been witnessing high demand for regenerative wound care products. One of the key trends in the market is the increasing adoption of acellular dermal matrices to treat complex wounds such as diabetic foot ulcers, pressure ulcers, and surgical & traumatic wounds. Acellular dermal matrices help regenerate lost or damaged dermal tissue and accelerate wound healing process by promoting cell proliferation. The adoption of acellular dermal matrices is growing owing to their ability to minimize donorsite morbidity and provide optimal wound coverage.
SWOT Analysis
Strength: Acellular dermal matrices help heal complex wounds faster and reduce hospital stay and treatment costs. They promote tissue regeneration without causing additional damage to donorsite.
Weakness: Expensive prices of acellular dermal matrices can limit their adoption in developing regions. Rigorous regulatory approvals are required for new product launches.
Opportunity: Rising obesity rates and incidence of diabetic foot ulcers and pressure ulcers present an opportunuity. Increasing spend on wound care Products worldwide also provides growth opportunities.
Threats: Reimbursement policies hamper the market growth to some extent. Alternate wound healing products like biosynthetic skin substitutes are a threat.
Key Takeaways
The global Acellular Dermal Matrices Market is expected to witness high growth, exhibiting CAGR of 12.1% over the forecast period of 2023-2030, due to increasing prevalence of diabetes and related chronic wounds. The market was valued at US$ 8.8 Bn in 2023.
Regional analysis: North America currently dominates the market owing to increasing obese population in the US and Canada. Asia Pacific is expected to exhibit the fastest growth during the forecast period with China and India emerging as highly lucrative markets.
Key players: Key players operating in the acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
